Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
McKesson
Fish and Richardson
Farmers Insurance
Citi
Teva
Julphar
Argus Health
Queensland Health

Generated: February 23, 2019

DrugPatentWatch Database Preview

XOLAIR Drug Profile

« Back to Dashboard

Summary for Tradename: XOLAIR
Patents:91
Applicants:1
BLAs:1
Suppliers: see list1
Pharmacology for XOLAIR
Mechanism of ActionIgE-directed Antibody Interactions
Physiological EffectDecreased IgE Activity

US Patents for XOLAIR

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Genentech XOLAIR omalizumab VIAL 103976 001 2003-06-20 ➤ Sign Up ATOPIX THERAPEUTICS LIMITED (London, GB) ➤ Sign Up RX search
Genentech XOLAIR omalizumab VIAL 103976 001 2003-06-20 ➤ Sign Up SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) ➤ Sign Up RX search
Genentech XOLAIR omalizumab VIAL 103976 001 2003-06-20 ➤ Sign Up Knopp Biosciences LLC (Pittsburgh, PA) ➤ Sign Up RX search
Genentech XOLAIR omalizumab VIAL 103976 001 2003-06-20 ➤ Sign Up ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for XOLAIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
93138 Luxembourg ➤ Sign Up PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326
92780 Luxembourg ➤ Sign Up PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
CA 2016 00031 Denmark ➤ Sign Up PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
PA2015031 Lithuania ➤ Sign Up PRODUCT NAME: TRASTUZUMABAS IR REKOMBINANTINE ZMOGAUS HIALURONIDAZE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Deloitte
Merck
US Department of Justice
Mallinckrodt
Argus Health
Chubb
Fuji
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.